Exciting Presentation at the Genetic Medicines Conference
NEW YORK, Healios K.K. is thrilled to announce that Richard Kincaid, the Chief Financial Officer, will be making a presentation at the Chardan 9th Annual Genetic Medicines Conference. This event serves as a wonderful opportunity for patients, investors, and industry experts to engage with cutting-edge advances in genetic therapeutics and regenerative medicine.
Event Details
The conference is scheduled for a specific date, and it promises to attract a wide audience passionate about innovations in genetic medicines. Richard Kincaid's presentation will provide insights into Healios K.K.'s ongoing projects and future aspirations in the biotechnology field.
The live session will take place at 2:00 PM Eastern Time, and attendees will have the chance to access a webcast of the presentation. Individuals interested in participating are encouraged to visit Chardan's website for additional details.
About Healios K.K.
Established in 2011, Healios K.K. is a pioneering biotechnology company based in Japan focused on developing regenerative medicines. The mission of Healios is commendable: to create innovative therapies for patients facing diseases that currently have no effective treatments. With a strong commitment to advancing health care, Healios leads the way in exploiting the potential of stem cell technology for the benefit of patients in need.
MultiStem Technology
At the forefront of its offerings is Healios's proprietary product, MultiStem (HLCM051). This advanced cell therapy consists of multipotent adult progenitor cells known as MAPCs, derived from healthy adult donor bone marrow. Extensive research has shown that MultiStem possesses remarkable anti-inflammatory and immunomodulatory properties. It has been tested in hundreds of patients, showcasing both its safety and potential efficacy across multiple disease states, leading to promising results in clinical settings.
Innovations in iPSC Regenerative Medicine
In addition to MultiStem, Healios is pioneering the development of HLCN061, a cutting-edge NK cell treatment aimed at solid tumors. What sets this product apart is its enhancement through gene-editing technology, which has demonstrated substantial anti-tumor effectiveness in various animal studies. This promising therapeutic is approaching initial human testing, developed in partnership with Akatsuki Therapeutics.
Commitment to Patients
Healios K.K. continually seeks to broaden its portfolio of treatments that address not only oncology but also other significant medical needs. By establishing a gene-edited 'universal donor' iPSC line, Healios is poised to introduce next-generation therapies across diverse areas including immuno-oncology, ophthalmology, and severe liver ailments.
Company Leadership
Healios is guided by its esteemed leadership team, including Hardy TS Kagimoto as the Chairman and CEO. The firm, listed under TSE Growth Code 4593, is positioning itself as a formidable player in the biotechnology landscape, focusing on giving hope to patients through innovative and accessible healthcare solutions.
Contact Information
Interested parties are invited to reach out with inquiries. Contact U.S. Investor Relations through Lisa M. Wilson at 212-452-2793 or via email at lwilson@insitecony.com.
For further queries, reach out to Richard Kincaid, Executive Officer and Chief Financial Officer, via email at ir@healios.jp.
Frequently Asked Questions
What is Healios K.K. known for?
Healios K.K. is a leading biotechnology company in Japan focused on developing regenerative therapies using stem cells.
When will the conference presentation take place?
The presentation will occur during the Chardan 9th Annual Genetic Medicines Conference, and details about the timing will be available on Chardan's website.
What innovative products does Healios offer?
Healios has developed MultiStem, a cell therapy product, and HLCN061, an NK cell treatment enhanced by gene editing for solid tumors.
Who can I contact for investor relations inquiries?
For inquiries, please contact Lisa M. Wilson in U.S. Investor Relations or Richard Kincaid at their respective email addresses specified.
How does Healios contribute to patient care?
Healios aims to develop effective therapies for conditions with significant unmet medical needs, offering innovative solutions for patients.
